SYDNEY AIN: Open Payments
NPI 1043062268 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,195 in 41 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $500 · 2025 $1,195
Food & beverage: $1,103Education: $91
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $264 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $138 |
| Calliditas Therapeutics US Inc. | 4 | $134 |
| AstraZeneca Pharmaceuticals LP | 4 | $134 |
| Amgen Inc. | 4 | $113 |
| OPKO Pharmaceuticals, LLC | 4 | $91 |
| Lilly USA, LLC | 3 | $78 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $71 |
| Apellis Pharmaceuticals, Inc. | 2 | $44 |
| Vantive US Healthcare LLC | 1 | $35 |
Products named: JARDIANCE, TRYVIO, TARPEYO, FARXIGA, REPATHA, RAYALDEE, Kerendia, Renal - PD.
Industry payments across IL — which companies pay providers there.
